OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel CID Therapeutic, at AACR

- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for chemotherapy-induced diarrhea


SEATTLE, March 8, 2022 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy company developing innovative medications to address unmet needs in oncodermatology and oncogastroenterology (cancer therapy-induced side effects occurring in the skin and gastrointestinal tract, respectively) and to improve quality of life for patients receiving anticancer medications, today announced it will be giving an oral presentation highlighting preclinical data for its therapeutic candidate OQL051, a gut-restricted CDK4/6 inhibitor for the prevention of chemotherapy-induced diarrhea (CID), at the American Association for Cancer Research (AACR) Annual Meeting 2022. The conference will be held in New Orleans, La., and virtually from April 8-13, 2022.


CID is one of the most common side effects of chemotherapy, with a reported incidence rate as high as 80% depending on the chemotherapy agent. Cancer patients experiencing diarrhea have a 40% higher rate of therapy discontinuation compared to those who do not. To address this significant unmet need, OnQuality is developing OQL051, a gut-restricted CDK4/6 inhibitor with the potential to prevent CID without affecting anti-cancer efficacy. At AACR, OnQuality will present preclinical data from in vitro and in vivo experiments showing that OQL051 had significant efficacy in protecting gastrointestinal tissues from damage and decreasing diarrhea caused by chemotherapy. Furthermore, pharmacological data revealed that OQL051 concentrations were 100 to 300 times higher in the jejunum and colon than in plasma, demonstrating its ability to target the intestinal tract thereby minimizing the potential to antagonize systemically administered chemotherapy regimens.


"OnQuality is committed to developing OQL051 for the prevention of CID, which will ultimately lead to improvements in patient quality of life and treatment outcomes. Our preclinical data demonstrate that the novel approach of OQL051 is an innovative solution that will prevent diarrhea while protecting gastrointestinal tissue from chemotherapy damage while minimizing the potential to interfere with systemically administered chemotherapy regimens" said Robert C. Tyler, Ph.D., Senior Medical Director of OnQuality. "I look forward to presenting these data at AACR and engaging in meaningful scientific discussions about the need for CID prevention at the conference with other industry leaders."

Details regarding the oral presentation can be found on the AACR website and below.


Presentation Details

Title: OQL051, a gut-restricted CDK4/6 inhibitor has prophylactic potency for chemotherapy-induced diarrhea Presented By: Robert C. Tyler, Ph.D. Session Category: Experimental and Molecular Therapeutics Session Title: Promising New Therapies Session Date and Time: Tuesday, Apr 12, 2022, 2:30 PM - 4:30 PM Abstract Number: 3593


About OnQuality Pharmaceuticals

OnQuality Pharmaceuticals is dedicated to pioneering the discovery and development of targeted supportive oncology therapies that address treatment-related toxicities at their molecular source. By treating on-target toxicities of the anti-cancer treatments, OnQuality's targeted supportive therapy candidates have the potential to reduce the severity and incidence of adverse events while sustaining the efficacy of the cancer treatments. OnQuality's targeted therapies, therefore, have the potential to improve both quality of life and outcomes for cancer patients.


OnQuality is leveraging its proprietary, AI-enabled CARE (Computation-Aided dRug-target-toxicology sEarch methodologies) platform to identify targets and drug candidates, to develop first-in-disease targeted supportive therapies addressing unmet medical needs in the emerging areas of oncodermatology and oncogastroenterology. This includes VEGFR inhibitor-induced Hand-Foot Skin Reaction, capecitabine-induced Hand-Foot Syndrome, epidermal growth factor receptor (EGFR) inhibitor-induced skin rash, chemotherapy-induced diarrhea and gastrointestinal side effects of immunotherapies. For more information about OnQuality Pharmaceuticals, please visit www.onqualityrx.com.


Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or other similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Although forward-looking statements contained herein are based on what OnQuality Pharmaceuticals believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. OnQuality undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

SOURCE OnQuality Pharmaceuticals